Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - Yake Biotechnology

Next Previous
Search
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Yake Biotechnology

Alternative Names: Anti-CD19 CART cell therapy - Yake Biotechnology

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yake Biotechnology
  • Developer Yake Biotechnology; Zhejiang University
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in China (Parenteral)
  • 27 Jan 2025 Zhejiang University initiates an early phase I trial for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in China (NCT06793241)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top